Bruker Co. (NASDAQ:BRKR) Stock Position Increased by Geode Capital Management LLC

Geode Capital Management LLC increased its holdings in Bruker Co. (NASDAQ:BRKR - Free Report) by 1.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,013,741 shares of the medical research company's stock after buying an additional 20,273 shares during the period. Geode Capital Management LLC owned about 1.33% of Bruker worth $118,081,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in shares of Bruker in the fourth quarter valued at $63,378,000. Vaughan Nelson Investment Management L.P. raised its position in shares of Bruker by 140.3% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 1,141,762 shares of the medical research company's stock valued at $66,930,000 after buying an additional 666,617 shares during the last quarter. State Street Corp lifted its stake in shares of Bruker by 9.6% during the third quarter. State Street Corp now owns 3,627,300 shares of the medical research company's stock valued at $250,501,000 after buying an additional 318,808 shares during the period. JPMorgan Chase & Co. grew its stake in Bruker by 139.3% in the 4th quarter. JPMorgan Chase & Co. now owns 526,166 shares of the medical research company's stock worth $30,844,000 after acquiring an additional 306,282 shares during the period. Finally, Brown Brothers Harriman & Co. raised its holdings in Bruker by 37.8% in the 4th quarter. Brown Brothers Harriman & Co. now owns 829,763 shares of the medical research company's stock valued at $48,641,000 after acquiring an additional 227,619 shares during the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Bruker Stock Up 1.8 %

Shares of Bruker stock traded up $0.69 during trading on Friday, reaching $38.76. The company had a trading volume of 3,139,890 shares, compared to its average volume of 1,467,987. The company has a market cap of $5.88 billion, a price-to-earnings ratio of 51.00, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. Bruker Co. has a fifty-two week low of $34.10 and a fifty-two week high of $90.03. The firm's fifty day moving average is $46.16 and its 200-day moving average is $54.75. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60.

Bruker (NASDAQ:BRKR - Get Free Report) last released its earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, topping analysts' consensus estimates of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. On average, analysts anticipate that Bruker Co. will post 2.69 EPS for the current year.

Bruker Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Monday, March 17th were paid a dividend of $0.05 per share. The ex-dividend date was Monday, March 17th. This represents a $0.20 annualized dividend and a yield of 0.52%. Bruker's payout ratio is 26.32%.

Analysts Set New Price Targets

Several equities analysts recently commented on BRKR shares. Stifel Nicolaus dropped their target price on Bruker from $70.00 to $57.00 and set a "hold" rating for the company in a research note on Friday, February 14th. Barclays lowered their price objective on shares of Bruker from $60.00 to $50.00 and set an "overweight" rating for the company in a research note on Thursday. Guggenheim reiterated a "buy" rating on shares of Bruker in a report on Monday, February 24th. Finally, Citigroup decreased their price objective on shares of Bruker from $75.00 to $50.00 and set a "buy" rating for the company in a research note on Monday, April 7th. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $66.50.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.